We read with great interest the review by Pepels et al. [1] on the safety of withholding axillary lymph node dissection (ALND) to the patients with clinically node-negative breast cancer. According to the survival and local control results from the NSABP B-32 randomised phase 3 trial [2] the authors concluded that in the patients with T1 or small T2 sentinel node (SN)-negative breast cancer omission of ALND can be regarded as safe. They pointed out that there is a shift toward omitting completion ALND in SN-positive patients but estimated that in SN-positive series the overall axillary recurrence rates were 2.8 times higher than for the SN-negative studies, and axillary recurrence rates after 5 and 8 years might be as high as 13 and 18%, respectively. They highlighted that in many patients with a positive SN withholding ALND may be not safe and that the role of systemic therapy have to be elucidated to establish a potential role for avoiding ALND in selected SN-positive cases.
To the Editor,
We read with great interest the review by Pepels et al. [1] on the safety of withholding axillary lymph node dissection (ALND) to the patients with clinically node-negative breast cancer. According to the survival and local control results from the NSABP B-32 randomised phase 3 trial [2] the authors concluded that in the patients with T1 or small T2 sentinel node (SN)-negative breast cancer omission of ALND can be regarded as safe. They pointed out that there is a shift toward omitting completion ALND in SN-positive patients but estimated that in SN-positive series the overall axillary recurrence rates were 2.8 times higher than for the SN-negative studies, and axillary recurrence rates after 5 and 8 years might be as high as 13 and 18%, respectively. They highlighted that in many patients with a positive SN withholding ALND may be not safe and that the role of systemic therapy have to be elucidated to establish a potential role for avoiding ALND in selected SN-positive cases.
Most of published studies on SN associated with ALND reported not insignificant prevalence of false-negative results, but the clinical consequences of these false-negative SN were fewer than expected. The discrepancy between prevalence of false-negative SN and lower prevalence of nodal recurrence in patients without definitive axillary treatment, the discrepancy between prevalence of axillary failure in clinically node-negative patients who do not undergo ALND and prevalence of positive nodes in clinically node-negative patients undergoing ALND have been partly attributed to the systemic therapies which are administered to the most SN-negative patients [3] [4] [5] . In contemporary practice of breast cancer treatment on the one hand there is a shift toward using systemic therapies as a substitute for potentially incomplete surgery (i.e., SN biopsy alone in SN-positive cases) more than as a complement to complete surgery. On the other hand, ratio of involved to total number of LNs (LNR) was found to be a better prognostic factor than the number of positive lymph nodes (LNs) for staging node-positive breast cancer in series of patients treated in era of systemic therapy [6] [7] [8] . An association between survival and extension of nodal dissection evaluated by the total number of the removed LNs, the number of removed uninvolved LNs, LNR with improvement in outcome in cases of more extended lymphadenectomy has been reported for melanoma and for colon, lung, gastric, pancreatic, esophageal, and breast cancers. LNR can minimize the stage migration produced by extended nodal dissection; using LNR rather than the absolute number of positive nodes reduces inter-institutional differences in outcome that may exist because of variations in the number of nodes excised. However, the best cut-off points of LN ratio required for a staging classification of each malignant tumor is controversial. Better prognosis has been reported with higher number of dissected normal nodes in histologically node-positive and -negative gastrointestinal tumors and several studies on breast cancer showed survival advantages after removal of many axillary nodes even if all regional nodes were pathologically negative [4, 9] . Although the Will Rogers effect (i.e., stage migration) was the most evident confounding factor, the prognostic improvement was attributed mostly to removal of nodes with micrometastases that were undetectable by routine histologic examination but which had prognostic impact. The concept of better prognosis by increase of the total number of dissected nodes and mostly by lowering of LNR (which minimizes the ''stage migration'' effect) supports the thesis of the therapeutic value of extended nodal dissection. However, whether or not ALND confers a survival advantage in breast cancer with micrometastatic or macrometastatic SNs in era of systemic therapy is questioned. Wasif et al. [10] showed that current ASCO guidelines recommending routine ALND following identification of micrometastasis in SNs are being followed in only 60% of cases and that the use of SN biopsy alone for axillary staging in cases of micrometastatic SNs may underestimate a 20% of patients with additional involved nonSNs revealed by ALND. The prognostic value of micrometastasis and isolated tumor cells (ITCs) in SNs in terms of associated additional positive nodes and distant recurrences is controversial. In the preliminary report from the EORTC 10981-22023 AMAROS Trial the further nodal involvement in patients with macrometastasis, micrometastasis, and ITCs in SNs was 41, 18%, and 18%, respectively [11] , according to the results of other studies underlined in the review by Pepels et al. [1] MaaskantBraat et al. [12] in their report on this Journal found no statistically significant difference in survival between patients with micrometastasis or ITCs in SNs compared to those patients with tumor-free SNs. However, in the study by de Boer et al. [13] ITCs and micrometastasis in regional LNs resulted to be associated with a reduced 5-year rate of disease-free survival among women with early-stage breast cancer who did not receive adjuvant therapy, without significant differences in outcome between ITCs and micrometastasis. Truong et al. [8] showed that similar to patients with macroscopic positive nodes, mortality hazards in patients with micrometastatic nodal disease increased with increased number of positive nodes and LNR.
Although the prognostic impact of micrometastasis and ITCs is under debate, it is known that the occurrence of locoregional failures confers poor prognosis [14] .
At present SN biopsy can be considered to be an effective procedure in the assessment of regional nodal status in clinically N0 cancer patients, and LNR considered to be the most effective prognostic factor that assesses the extent of therapeutic nodal dissection in node-positive tumors [15] . In breast cancer the concept of LNR cannot be consistent with the concept of SN biopsy if completion ALND is considered unnecessary in SN-positive patients, and if staging by SN biopsy is considered to be the only necessary surgical treatment for these patients. Moreover, performing SN biopsy alone in pN1 mi SN patients cannot be consistent with the prognostic value of LNR in pN1 mi : if the therapeutic or prognostic value of LNR in microscopically SN-positive tumors is accepted, completion ALND will have to be done in all SN-positive tumors (apart from micrometastatic or macrometastatic SNs). In fact the risk of additional non-SN involvement associated to micrometastatic SN involvement is not negligible: SN biopsy improves pathological nodal assessment detecting otherwise misdiagnosed nodal micrometastases by adopting multistep sectioning, immunohistochemistry or RT-PCR but it should be considered that if these same techniques are applied to non-SNs, the false-negative rate of SNs will increase.
In conclusion avoiding completion ALND in patients with micrometastatic or macrometastatic SNs is not consistent with the concept of LNR as a prognostic factor in these patients. The potential role of systemic therapy for avoiding ALND in selected SN-positive patients need further to be elucidated but it should be considered that the prognostic value of LNR in identifying higher-risk nodepositive cases warranting more aggressive systemic therapy may be estimated only by ALND. To the Editor,
We like to thank Dr. Peparini and Dr. Chirletti for their interesting letter-to-the-editor regarding our systematic review on the safety of avoiding routine use of axillary lymph node dissection (ALND) in early breast cancer patients [1, 2] . They agree on our conclusion that omitting ALND in sentinel node (SN) negative patients can be considered a safe strategy. Further, they also fully agree with our second message, that in SN-positive patients still many issues need to be solved before omission of ALND can be recommended to all these patients.
Dr. Peparini and Dr. Chirletti argue that there are two additional reasons why ALND cannot be omitted in SNpositive patients, besides low number of patients followed up and the absence of well-defined selection criteria to be used. The first additional argument concerns the lack of information on the lymph node ratio (LNR) if no completion ALND is performed. The second argument concerns possible changes in systemic treatment choices depending on ALND, and more specifically treatment choices related to the presence of isolated tumor cells (ITCs) and micrometastases. Although we share the same vision on the preferred strategy in SN-positive patients, we are not convinced that the aforementioned arguments really further support our conclusion.
The LNR is the ratio of positive to excised number of nodes. Many studies have reported that in breast cancer the LNR is a stronger prognosticator than the absolute number of positive nodes [3] [4] [5] [6] . With more negative nodes being removed, the LNR reduces and prognosis improves. In addition, several studies have shown that also in nodenegative patients clinical outcome is associated with number of (negative) nodes excised [7, 8] . The argument in favor of an extensive ALND is that if more nodes are excised also microscopic disease is resected, preventing outgrowth and dissemination of disease. As such, ALND might offer therapeutic benefit. On the other hand, there may be stage migration when more nodes are removed, for example in the patients with two resected SNs that are both positive that could actually have a larger number of positive nodes if only more nodes would have been investigated. So, the meaning of ''two positive'' nodes is different for patients with more versus those with less nodes excised. This latter concept relates the improved outcome of extensive ALND to the more accurate staging process and not necessarily to a therapeutic effect of ALND. This latter hypothesis may, however, not be relevant for patients who have undergone an SN procedure. The SN is by definition already a more accurate staging procedure than conventional ALND, and therefore, the number of negative nodes removed may be less relevant. A recent study that compared survival between pN0 breast cancer patients who had undergone more or less extensive ALND and pN0 patients who had an SN procedure confirmed this. Although extensive ALND was associated with better survival than limited ALND, SN only patients also had an excellent survival [7] .
The second issue concerns the question of non-SN involvement, including macrometastatic disease, in case of SN ITCs and micrometastases and if such additional information would change adjuvant systemic therapy choices. The chance of further lymph node metastases beyond the SN is 12.3% in case of SN ITCs (64% macrometastases) and 20% in case of micrometastases [9] . Previously, we have shown in the Dutch MIRROR study that ITCs and micrometastases as final nodal status are significantly associated with increased risk of disease events at a hazard ratio of about 1.5 as compared with the patients having node-negative disease [10] . Some other SN studies could [11, 12] , but some could not confirm this association between micrometastatic disease and clinical outcome [13] [14] [15] . However, it is noted that the MIRROR study is by far the largest SN study on prognostic relevance of ITCs and micrometatases, with outcome being assessed in the patients who had not received systemic therapy and SN classification on full central pathology revision, and by such offering the most robust data on this issue. Moreover, a comparable hazard ratio of around 1.45 was seen in a meta-analysis on studies from the pre-SN era [16] . Therefore, we recommend to consider the use of adjuvant systemic therapy in these patients, and think that systemic treatment choices should not depend on the number of positive nodes that have been detected.
To conclude, we agree with Peparini and Chirletti that for most patients it is yet too soon to routinely implement omission of ALND in SN-positive patients. Although many questions still need to be addressed, we are not convinced that LNR is an important factor when the SN procedure is being used.
